ICIs target cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) or programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathways to disrupt tumor immune evasion (1). Here, CTLA4 is linked to neoplasm.